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Background: Systemic drugs-like oral montelukast can reach lower airways, whose
inflammation plays a crucial role in the evolution of asthma, while inhaled drugs
hardly reach them. The impulse oscillometry (IOS) technique is useful to evaluate
both central and peripheral airways function.
Objective: To measure the effect of oral montelukast on airways resistance
evaluated by oscillometry in children with asthma.
Methods: In an open study, respiratory function in 23 children with mild asthma and
a positive bronchodilator response was assessed by spirometry and oscillometry.
They took oral montelukast during 4 weeks and were again evaluated. As a control
group, 23 similar patients with no preventive treatment underwent the same study.
Measurements and main results: Children on oral montelukast showed improve-
ments (measured in kPa s L1) in all oscillometry parameters: mean 0.20 (22.4%) in
total respiratory impedance Zrs5, 0.18 (21.8%) in total airway resistance Rrs5, 0.09
(17.8%) in central airway resistance Rrs20, and 0.09 (28.8%) in distal capacitive
reactance Xrs5; the frequency of resonance Fres improved 2.3 Hz (8.7%) (Po0:05 in
all cases). No changes were found in the control group. Expiratory flows showed no
changes except for a small (0.23 L s1, 7.4%) but significant worsening of FEF25–75 in
the control group.
Conclusions: Montelukast improves central and especially peripheral airways function
in the first month of treatment, as evaluated by IOS, a technique based on tidal
breathing analysis which is more sensitive than conventional forced spirometry.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
1973258; fax: +34 96 1973258.
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Montelukast decreases airway resistance 1181Introduction montelukast or no preventive treatment duringThe inflammation of airways is the underlying
pathogenetic mechanism of asthma. This inflamma-
tion usually affects the whole respiratory tract,
from the nose down to the most distal airways and
alveolar tissue.1–4 The peripheral airways have been
called the ‘‘silent zone’’, due to the paucity of non-
invasive methods to evaluate their function and
condition. Nevertheless, they have been recognized
as a crucial site responsible for many of the most
relevant pathophysiologic features of asthma.5–11
Additionally, it has been pointed out that inhaled
medication hardly reaches these peripheral air-
ways, and that an alternative would be the use of
systemic anti-inflammatory approaches.2,4
The inflammation of airways gives rise to bronchial
hyperreactivity and to increases of resistance to
airflow, hence functional respiratory studies are used
as surrogate evaluators of inflammation. Impulse
oscillometry (IOS) is quite a recent technique which
allows for respiratory functional studies, without
forced maneuvers, performed at spontaneous
breathing and therefore requires minimal coopera-
tion. Thus, respiratory function can be studied in
small children, even as young as 3–6 years. The IOS
technique measures changes in airway impedance
while the device emits impulse shaped sound signals
which contain frequencies at various wavelengths.
The main parameters thus obtained reflect the total
pulmonary impedance (Zrs5), the total respiratory
resistance (Rrs5), the central airways resistance
(Rrs20), the distal capacitive reactance (Xrs5), and
the frequency of resonance (Fres).12 As there is
nearly no measurable resistance in the peripheral
compartments of the lung, the elastic properties are
indirect indicators of peripheral obstruction, ex-
pressed in a negative shift of the parameter Xrs5.
There are studies evaluating the response to
bronchodilators or inhaled steroids with the IOS
technique, but there is none, to our knowledge,
evaluating the effect of antileukotrienes. The aim
of our work was to study the effect of montelukast
on the IOS parameters, to evaluate the impact of
this drug in children with mild asthma, since these
parameters have been recognized as indirect
measures of the inflammation of the airways. The
main endpoint was the change in Xrs5, because it
has been proposed as representative of the
inflammation of the distal airways.13Methods
We performed an open study, in which 46 children
with mild asthma were randomized to receive4 weeks. The inclusion criteria were: age over
5 years, three or more episodes of asthma in
the previous year, no symptoms at the time of the
study, no use of antiasthmatic medication in the
previous month, FEV1480% of predicted, and a
baseline bronchodilating response of at least one of
the following: increase of 412% in FEV1, 412% in
PEF, 425% in FEF25–75, 425% in Xrs5, decrease of
425% in Rrs5.
An IOS and spirometry study was done, according
to the ERS Task Force recommendations.14 For IOS,
a Jaeger MasterScreen Impulse Oscillometry System
(Jaeger Co, Wurzburg, Germany) was used. In brief,
the child spontaneously breathes during 30 s
throughout the IOS head, with a nose clip and
pressing his/her cheeks with both hands, while a
loudspeaker in the head of the system emits sound
impulses every 0.2 s. These pressure fluctuations
are superimposed on the breathing pattern and
measured as central flow with the help of a Lilly
type pneumotachograph, and as mouth pressure
with a differential pressure transducer, and they
are fed into a fast Fourier transformation. The
relation of pressure and flow signal permits
measurement of impedance of the total respiratory
system (Zrs5), and from this, the total (Rrs5) and
the central (Rrs20) airways resistances, and the
reactance (Xrs5) can be calculated.15 The number
in the parenthesis indicates the wavelength at
which measures are made. The point where the
usually negative reactance reaches 0, measured in
Hertz, is called the frequency of resonance (Fres).
The Xrs5 reactance best represents the condition of
peripheral airways. Also, as Rrs5 is thought to
reflect total airway resistance and Rrs20 proximal
resistance, the difference Rrs5Rrs20 might be
used as a surrogate of the resistance of the small
airways. The reference values of Duiverman were
used for those below 6 years.16 From 7 years
reference values of Berdel/Lechtenboerger were
available (data not published). For spirometry, a
pneumotachometer system (MasterScreen Pneumo
Jaeger, Wurzburg, Germany) was used. The best
flow-volume curve, from at least three trials was
selected, according to ATS criteria modified by
Arets et al.17 and Eigen et al.18 The reference
values of Zapletal et al. were used.19 Two inhala-
tions of salbutamol 100mcg were administered
through a spacer device, and the bronchodilating
response was assessed 20min later with IOS and
spirometry.
A prescription of montelukast (Merck, New
Jersey, USA) was made at the first visit, and
patients were instructed to take montelukast once
a day (4mg when under 6 years, 5mg for those
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every evening during 4 weeks, and the same
functional respiratory study was repeated there-
after. Compliance of treatment was evaluated by
interviewing patients and parents. The control
group of patients, in whom the preventive treat-
ment was delayed for 1 month, underwent the
same tests. The study was approved by the local
Ethics Committee, and informed consent was
obtained from parents and older children.
Statistical study
The C-4 Study Design Pack (GSK) was used to
calculate the sample size for paired data, with an
a-error of 0.05 and a b-error of 0.1, to detect a
change of 20% in the main variable (Xrs5) and also a
change of 15% in FEV1 and FEF25–75. The statistical
analysis was performed with the SPSS 10.0 statis-
tical package (SPSS Inc., Chicago, IL, USA). Com-
parisons of data, separated for active and control
group, between first and second visit were assessed
with paired T-test, or its equivalent non-parametric
Wilcoxon rank test for data with non-normal
distribution. Values of Po0:05 were considered as
significant.Results
Both the active and the control groups included 23
children each. As shown in Table 1, no statistical
difference at baseline for demographic and func-Table 1 Baseline demographic and functional character
Control group
Gender (F/M) 10/13
Age (years) 9.7472.76
Age:o6/6–14/414 years 3/19/1
Duration of asthma (years) 5.372.7
Weight (kg) 37.66715.98
Height (cm) 137.9716.3
FEV1 (L) 2.0970.63
PEF (L s1) 4.2971.27
FEF25–75 (L s1) 2.3470.88
Zrs5 (kPa s L1) 0.8770.22
Rrs5 (kPa s L1) 0.8170.21
Rrs20 (kPa s L1) 0.5470.15
Rrs5Rrs20 (kPa s L1) 0.2770.18
Xrs5 (kPa s L1) 0.2870.11
Fres (Hz) 20.374.5
P: non-significant for all data.
Dose of montelukast: *4mg/day; y5mg/day; z10mg/day.
Fres: Frequency of resonance.tional characteristics was found. Besides the
absolute figures, the percentages of predicted
values, depicted in Table 2, were similar for the
two groups, as well as the bronchodilating response
at baseline (not shown). The number of patients
fulfilling the basal bronchodilating response criteria
for inclusion did not differ between the active and
the control group, and were respectively, 4 and 5,
for improvement in FEV1, 10 and 6 in PEF, 8 and 10
in FEF 25–75, 14 and 9 in Rrs5, and 16 and 12 in Xrs5
(P40:1 in all).
The difference for functional data between the
first and the second visit, after four weeks, can be
seen in Table 3 for both control and active groups.
No change was seen in the IOS parameters in the
control group; there was a trend for worsening in
the spirometry data, which was small but statisti-
cally significant for FEF25–75. By contrast, in the
montelukast group we found a significant improve-
ment in all IOS parameters, especially in reactance
Xrs5, whose change is shown in Fig. 1. There was a
trend for improvement also in the spirometry data,
especially for FEF25-75, although not to a signifi-
cant degree.Discussion
Most of the resistance of the airways to airflow
depends on the proximal bronchi, so it is difficult
to assess increases of the resistance of the low air-
way. Nevertheless, several clinical features have
been proposed as correlates of the small airwaysistics; results in absolute units.
ðn ¼ 23Þ Montelukast group ðn ¼ 23Þ
11/12
9.6873.01
3*/19y/1z
5.873.3
40.17714.24
138.4717.3
2.1470.74
4.5271.69
2.4871.14
0.8970.25
0.8370.24
0.5270.14
0.3170.20
0.3170.12
21.973.3
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Table 2 Baseline functional parameters, in percentage of predicted.
Control group Montelukast group
FEV1 (%) 106.9710.7 109.5715.9
PEF (%) 94.9712.67 99.9719.18
FEF25–75 (%) 93.9725.9 99.4730.6
Zrs5 (%) 115.7723.9 117.6722.6
Rrs5 (%) 115.57723.35 116.79722.72
Rrs20 (%) 103730.1 96.25727.69
Xrs5 (%) 116.5739.3 125.8733.2
P: non-significant for all data.
Table 3 Mean increases or decreases (negative sign) in absolute values (% in parenthesis) from the first to the
second visit.
Control group Montelukast group
FEV1 (L) 0.06 (2%) 0.04 (2.9%)
PEF (L s1) 0.22 (4.5%) 0.03 (3.9%)
FEF25–75 (L s1) 0.23 (7.4%)* 0.17 (10.9%)y
Zrs5 (kPa s L1) 0.034 (3.9%) 0.20 (22.4%)z
Rrs5 (kPa s L1) 0.036 (4.5%) 0.18 (21.8%)z
Rrs20 (kPa s L1) 0.02 (3.7%) 0.09 (17.8%)z
Rrs5Rrs20 (kPa s L1) 0.017 (0.52%) 0.089 (13.6%)z
Xrs5 (kPa s L1)y 0.0009 (0.3%) 0.09 (28.8%)z
Fres (Hz) 0.44 (4.3%) 2.3 (8.7%)#
Comparisons within group with baseline:
*P ¼ 0.035. yP ¼ 0.11. zPo0.001. zP ¼ 0.005. #P ¼ 0.025. All the rest: P40.20.
y:As Xrs5 reactance has usually negative values, increases are associated with improvement.
Fres: Frequency of resonance.
Basal 4 weeks Basal 4 weeks
CONTROL (N=23)
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MONTELUKAST (N=23)
p < 0.001
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Figure 1 Increases in capacitive reactance Xrs5 in the control and in the montelukast group.
Montelukast decreases airway resistance 1183condition, namely nocturnal asthma,7,20,21 cold air
and exercise-induced asthma,22 asthma exacerba-
tions,23 and persistent wheezing in children.24 In
conventional spirometry, it is commonly accepted
that the mid-expiratory flows best reflect the
function of the small caliber airways. However,
the requirement of forced expiratory maneuversmakes its evaluation difficult, especially in younger
patients, and other methods have been developed
for assessment of their function.
The technique of IOS takes advantage of the
changes in airflow when the airways are subjected
to sound impulses. These changes with different
wavelength impulses are measured to calculate
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total system impedance (Zrs5), the total airway
resistance (Rrs5) and the peripheral capacitive
reactance (Xrs5) can be estimated, while the large
caliber airway resistance (Rrs20) is best assessed at
20Hz wavelength.25–27 Changes in airway resis-
tance usually precede changes in airflow, and it has
been estimated that at least increases of 40–50% in
airway resistance are comparable to a decrease of
20% detected in spirometry studies.28–30 The IOS
technique is, hence, more sensitive to recognize
the early subtle changes in the airways arising from
the underlying inflammation of asthma. In fact, at
low oscillation frequencies, elastic elements in
peripheral airways are the dominant reactant to
applied pressure, and reflect small airway mechan-
ical properties. In airway obstruction, small airways
are functionally obstructed, due to peripheral
airway inflammation. Accordingly, changes in low-
frequency Xrs rather reflect peripheral airway
disease.13 This, together with the ease of perform-
ing the technique makes IOS a very valuable tool for
the assessment and follow-up of asthma, especially
in children.
Inhaled corticosteroids are the most potent anti-
inflammatory drugs used for treatment of asthma,
but there is concern about their side effects.
Additionally, in patients with bronchial obstruction
inhaled drugs hardly reach the peripheral airways
and the distribution of aerosol is uneven and
predominant in the large central airways.31,32
Leukotriene receptor antagonists, such as monte-
lukast, have a lower anti-inflammatory effect, but
a better safety profile, and since they are orally
given, they can reach the whole airways. This
confers them a special advantage for the treatment
of distal airways disease.
In our study montelukast decreased all measured
IOS parameters, in the first month of treatment.
Improvements were found in parameters evaluating
the whole (Zrs5 and Rrs5), the central (Rrs20) and
the distal airways (Rrs5Rrs20 and Xrs5) function,
but were most marked for the latter. There was a
moderate, though not significant, improvement for
the FEF25–75, in accordance with its ability to
evaluate small airways function. As expected, no
effect was seen in the control group, except for a
small but significant worsening of the FEF25–75.
Both groups were comparable at baseline, and
the end-point was an objective measure, so, even
though it was an open study, the bias should be
limited. The variability of the IOS technique,
estimated at around 10.5%,33 could weaken our
findings, but the striking differences between the
groups reinforce them, especially when considering
that the number of patients in each group was notlarge. The conditions of the study were those of
real life, thus results should be more applicable to
the common asthmatic patients.
Our patients had mild persistent asthma and had
no symptoms at the time of the study, but they had
a positive bronchodilating test and their airways
resistance decreased with preventive treatment,
thus disclosing a subclinical inflammation of the
airways. This bronchial subclinical inflammation
has been described in asymptomatic asthmatic
patients,34,35 and, using sophisticated methods,
physiologic abnormalities have been demonstrated
in the peripheral airways of asymptomatic adult
patients with mild asthma and normal conventional
lung function tests.5 Current guidelines do not
recommend preventive treatment for patients with
mild intermittent asthma, but studies are war-
ranted to evaluate the degree of involvement of
airways and their response to anti-inflammatory
therapy. This could eventually justify the use of
preventive treatment able to reach the peripheral
airways in these patients, even though they are
asymptomatic.
In conclusion, this study demonstrates the
decrease of airways resistance by the therapy with
oral montelukast in asthmatic children, as mea-
sured by IOS. This effect was found in the whole
airway, but was more pronounced on the distal
bronchi. It appeared after a short period of only
one month of treatment. The role of montelukast in
the treatment of adult and childhood asthma
remains to be well established. Issues such as
clinical effectiveness, compliance, cost, side ef-
fects and long-term outcome must be considered.
Our data provide evidence that, at least in the
short term, montelukast can reduce airway resis-
tance, one of the major pathophysiologic mecha-
nisms of asthma.Acknowledgment
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